Scientists Have Figured Out How to Use the Herpes Virus to Fight Skin Cancer

Scientists Have Figured Out How to Use the Herpes Virus to Fight Skin Cancer
Source: Yale Rosen
Source: Yale Rosen

On Tuesday, the Food and Drug Administration approved a drug that uses the herpes simplex virus to sneak into — and annihilate — skin cancer cells.

Studies conducted by manufacturer Amgen Inc. show the drug, Imlygic, shrunk melanomas in about "about 16% of patients injected with the drug ... compared with 2% of patients who took more conventional cancer drugs," CBS News reports. It has no effect on skin cancer that has spread to other regions of the body.

Amgen Inc. told CBS News one course with the drug would cost approximately $65,000.

Imlygic piggybacks into skin-cancer cells using a modified herpes virus and then replicates rapidly, destroying the cells from within, at the same time triggering the body's immune system into a heightened response against skin tumors.

In an announcement on its website, the FDA hailed Imlygic as the "first FDA-approved oncolytic virus therapy" and noted 74,000 Americans are diagnosed with and 10,000 Americans die from melanoma annually.

"Melanoma is a serious disease that can advance and spread to other parts of the body, where it becomes difficult to treat," Research Dr. Karen Midthun, director of the FDA's Center for Biologics and Research, wrote in the statement. "This approval provides patients and health care providers with a novel treatment for melanoma."

However, side effects noted by the FDA included "fatigue, chills, fever, nausea, flu-like symptoms and pain at the injection site" as well as possible herpes virus infection.

According to the Skin Cancer Foundation, "more people have had skin cancer than all other cancers combined" over the past three decades, and it is the only one of the seven most common types of cancer that is becoming more common. The foundation notes approximately 40 to 50% of people who live to age 65 or older will experience the non-melanoma skin cancers of either basal cell carcinoma or squamous cell carcinoma "at least once."

How much do you trust the information in this article?

Tom McKay

Tom is a staff writer at Mic, covering national politics, media, policing and the war on drugs. He is based in New York and can be reached at tmckay@mic.com.

MORE FROM

Despite Trump, military leaders say there will be no changes to transgender policy for now

“In the meantime, we will continue to treat all of our personnel with respect."

Trump will visit Long Island to discuss gang violence — but some fear he could make the issue worse

Trump has celebrated mass deportations as fighting gang violence — but are his words helping or hurting?

Like his boss, Anthony Scaramucci seems to be a fan of disgraced football coach Joe Paterno

President Donald Trump also gave a shout-out to the late Penn State coach during the 2016 campaign.

Ride malfunction at Ohio State Fair leaves 1 dead, 7 injured

The ride reportedly broke apart while in motion.

Despite Trump, military leaders say there will be no changes to transgender policy for now

“In the meantime, we will continue to treat all of our personnel with respect."

Trump will visit Long Island to discuss gang violence — but some fear he could make the issue worse

Trump has celebrated mass deportations as fighting gang violence — but are his words helping or hurting?

Like his boss, Anthony Scaramucci seems to be a fan of disgraced football coach Joe Paterno

President Donald Trump also gave a shout-out to the late Penn State coach during the 2016 campaign.

Ride malfunction at Ohio State Fair leaves 1 dead, 7 injured

The ride reportedly broke apart while in motion.